Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

Inclusion Criteria:

• Clinical diagnosis of HF requiring chronic treatment of loop diuretics
• Left Ventricular Ejection Fraction (LVEF) ≤ 40% at screening by echocardiography
• N-Terminal-prohormone of Brain Natriuretic Peptide (NT-proBNP) ≥400 pg/mL at screeningfor patients without atrial fibrillation or atrial flutter, or, NT-proBNP ≥ 1,200pg/mL at screening for patients with atrial fibrillation or atrial flutter
• Treated for Heart Failure with stable, optimal pharmacological therapy
• Acceptable screening echocardiographic image quality

Exclusion Criteria:

• Female patients of childbearing potential
• Patients with a New York Heart Association (NYHA) Class I or IV
• Heart failure that is clearly caused by toxin / drug such as Adriamycin
• Significant medical conditions or recent history suggesting the patient's studyparticipation will potentially pose a major risk to patient's safety and well-being
• Need for routine scheduled outpatient IV infusions for Heart Failure or scheduledultrafiltration
• History of rhabdomyolysis or history of autoimmune diseases
• Severe renal disease
• Hepatic disease
• Pulmonary disease limiting exercise capacity
• Atrial fibrillation with rapid ventricular response
• Life expectancy of less than 6 months
• Type 1 diabetes mellitus or Type 2 diabetes mellitus with very poor glycemic control
• Patients with anemia